ONX-0801

ONX-0801
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number	501332-69-0
PubChem	11671880
DrugBank
ChemSpider
KEGG

ONX-0801 (BGC 945) is an experimental drug that has been developed to target ovarian cancer.<ref>

Ovarian cancer drug delivers ‘very promising’ results in early trial(link). The Institute of Cancer Research, London.

3 June 2017.

Accessed 2017-06-03.

</ref> It is a folate receptor alpha mediated thymidylate synthase inhibitor.<ref> ,

 A Phase I trial of ONX-0801 Full text, 
 Health Research Authority, 
  
 19 July 2013, 
  
  
 Accessed on: 2017-06-03.

</ref><ref>Jarmula A. Antifolate inhibitors of thymidylate synthase as anticancer drugs. Mini Reviews in Medicinal Chemistry 10.13 (2010): 1211-1222. </ref>

ONX-0801 was originally developed by BTG and the Institute of Cancer Research in the UK, and subsequently licensed to Onyx Pharmaceuticals for clinical development. It is designed to selectively target tumour tissues of certain kinds of cancer.<ref>Gibbs DD, Theti DS, Wood N, Green M, Raynaud F, Valenti M, Forster MD, Mitchell F, Bavetsias V, Henderson E, Jackman AL. BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors. Cancer Res. 2005 Dec 15;65(24):11721-8. </ref> It is poorly absorbed into most cells, but is actively transported by folate receptor alpha (FRα), which is usually only expressed at low levels in the apical membrane of some specialised tissues, but is expressed at much higher levels in some subtypes of ovarian cancer. This causes the drug to accumulate selectively in tumour tissues, while healthy tissues are only exposed to a much lower concentration.<ref>Ng C, et al. Efficacy and tolerability of the thymidylate synthase (TS) inhibitor, BGC 945 is mediated through its selective uptake via the α-folate receptor (α-FR) in IGROV-1 human tumor xenografts. Cancer Res May 1, 2008 (68) (9 Supplement): 3289.</ref><ref>Ng CHM, Jackman AL. Potential for α-Folate Receptor-Targeted Treatment for Ovarian Cancer. Emerging Therapeutic Targets in Ovarian Cancer. Springer New York, 2011. 245-258.</ref><ref>Tochowicz A, Dalziel S, Eidam O, O'Connell JD 3rd, Griner S, Finer-Moore JS, Stroud RM. Development and binding mode assessment of N-[4-[2-propyn-1-yl[(6S)-4,6,7,8-tetrahydro-2-(hydroxymethyl)-4-oxo-3H-cyclopenta[g]quinazolin-6-yl]amino]benzoyl]-l-γ-glutamyl-D-glutamic acid (BGC 945), a novel thymidylate synthase inhibitor that targets tumor cells. J Med Chem. 2013 Jul 11;56(13):5446-55. doi: 10.1021/jm400490e </ref>

In 2017, it received press coverage following the successful completion of a Phase I clinical trial.<ref> Warry, Richard,

 Drug shrinks ovarian tumours in early trial Full text, 
 BBC News, 
  
 2017-06-03, 
  
  
 Accessed on: 2017-06-03.

</ref><ref> ,

 Researchers hail biggest breakthrough in advanced ovarian cancer for a decade Full text, 
 The Independent, 
  
 2017-06-02, 
  
  
 Accessed on: 2017-06-03.

</ref><ref>Banerji U, et al. An investigator-initiated phase I study of ONX-0801, a first-in-class alpha folate receptor targeted, small molecule thymidylate synthase inhibitor in solid tumors. J Clin Oncol 35, 2017 (suppl; abstr 2503)</ref>

References

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia

   This article is a medical stub. You can help WikiMD by expanding it!